Eradra 5% ophthalmic solution
Generic: Lifitegrast
Company: General Pharmaceuticals Ltd.. Prices are as listed on BestinMeds; your pharmacy price may differ.
Reviewed by: not listed yet. Source: not listed yet.
Last updated September 7, 2024.
Generic: Lifitegrast
Company: General Pharmaceuticals Ltd.. Prices are as listed on BestinMeds; your pharmacy price may differ.
Reviewed by: not listed yet. Source: not listed yet.
Last updated September 7, 2024.
Sorted by price per ophthalmic solution. Ask your pharmacist before you switch brands.
Prices as listed on BestinMeds.
No price is listed for this strength yet.
Advertisement
What this medicine is for, how to take it, and what to watch for.
Read the full Lifitegrast guide
Dry eye Lifitegrast 5% ophthalmic solution is indicated for the treatment of the signs and symptoms of dry eye disease (DED).
Instill one drop of Lifitegrast twice daily (approximately 12 hours apart) into each eye. Contact lenses should be removed prior to the administration of Lifitegrast and may be reinserted 15 minutes following administration.
The common adverse effects are instillation site irritation, dysgeusia and reduced visual acuity. Less common are blurred vision, conjunctival hyperemia, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
Do not touch the dropper tip to surfaces since this may contaminate the solution. After one month of the opening do not use the medicine of dropper.
There are no available data on Lifitegrast use in pregnant women to inform any drug associated risks. There are no data on the presence of Lifitegrast in human milk, the effects on the breastfed infant or the effects on milk production.
Lifitegrast binds to the integrin LFA-1, a cell surface protein found on leukocytes and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1). ICAM-1 may be overexpressed in corneal and conjunctival tissues in DED. LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse resulting in T-cell activation and migration to target tissues. In vitro studies demonstrated that lifitegrast may inhibit Tcell adhesion to ICAM-1 in a human T-cell line and may inhibit secretion of inflammatory cytokines in human peripheral blood mononuclear cells. The exact mechanism of action of lifitegrast in DED is not known.
This information is not available. Ask your doctor or pharmacist.
Pediatric Use: Safety and efficacy in pediatric patients below the age of 17 years have not been established. Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger adult patients.
There is no information regarding overdose in patients taking Lifitegrast. For management of a suspected drug overdose, contact your ophthalmologist.
Other ophthalmic preparations
Store in a cool (below 30°C) and dry place, away from light. Keep out of the reach of children.
BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.
Advertisement
No other Eradra products are listed yet.
Advertisement